GCC Swollen Knee Treatment Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

GCC Swollen Knee Treatment Market Trends and Insights

Rising Knee Osteoarthritis Burden Across GCC Countries

Knee osteoarthritis (OA) in the GCC is no longer confined to the elderly, impacting both national and expatriate populations. Women often face a higher burden, and working-age adults are entering treatment earlier. Between 1990 and 2024, Bahrain and the UAE recorded some of the steepest global increases in knee OA incidence.^{[1]Emirates Hospitals Group, “PRP Injection Package for Knee, Elbow or Joint in Dubai,” Emirates Hospitals, emirateshospitals.ae} This long-term trend is driving repeated demand for analgesics, injections, rehabilitation, and imaging. As orthopedic access improves, the GCC swollen knee treatment market is expected to capture a larger share of untreated cases.

Growth In Obesity And Diabetes Linked To Joint Inflammation

High obesity and diabetes rates in the GCC are expanding the patient base for swollen knee treatments through mechanical stress and inflammation. From 2020 to 2024, over 65% of Saudi adults were classified as overweight or obese. In 2024, the MENA region had 84.7 million adults with diabetes, with a prevalence of 17.6%.^{[2]Anika Therapeutics, “Anika Therapeutics Touts $3B TAM, Cingal & Hyalofast Growth Plans at Canaccord MSK Conference,” The Lincolnian Online, thelincolnianonline.com} These conditions complicate treatment and follow-up care, increasing demand for precise dosing and specialist oversight in the GCC swollen knee treatment market.

Expansion Of Private Orthopedic And Sports Medicine Clinics

Private investments are transforming care delivery in the GCC, expanding access to swollen knee treatments. In 2025, Burjeel Holdings enhanced its Saudi rehabilitation network, while the Emirates Growth Fund acquired a minority stake in Tarmeem Healthcare, which serves over 20,000 patients annually. Ambulatory orthopedic sites are improving efficiency and access to outpatient care, reducing reliance on tertiary hospitals for routine interventions in the GCC swollen knee treatment market.

Wider Adoption Of Minimally Invasive Injection Therapies

Minimally invasive procedures are the fastest-growing segment in the GCC swollen knee treatment market, with a projected CAGR of 5.98% through 2031. Clinicians increasingly prefer viscosupplementation and platelet-rich plasma (PRP) as alternatives to surgery. A 2025 meta-analysis showed leukocyte-poor PRP outperformed hyaluronic acid in knee OA outcomes. Enhanced injection accuracy and follow-up systems are improving adherence to repeat procedures, further driving growth in the GCC market.

Limited Local Clinical Standardization For Swollen Knee Pathways

Inconsistent clinical standards across the GCC hinder efficient patient treatment. Referral practices vary significantly, leading to different treatment approaches for similar cases. This inconsistency impacts the adoption of premium therapies. Regulatory fragmentation further complicates product approvals and reimbursement processes, creating challenges for suppliers, especially with newer treatments. Without standardization, the GCC swollen knee treatment market will remain below its potential.

High Out-Of-Pocket Cost For Repeated Injection-Based Care

Repeated injection treatments are financially challenging for many patients, particularly where private insurance offers limited coverage. In Riyadh, PRP sessions cost between SAR 700 and SAR 4,000 (USD 186.7 to USD 1,066.7), while Dubai hospitals charge approximately AED 2,200 (USD 599.5). These costs increase with multiple sessions or ongoing therapy. Although coverage is better in the UAE and Saudi Arabia, affordability remains a key barrier, limiting market expansion despite strong clinical interest.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Treatment Type: Pharmacological Dominance Meets A Procedural Pivot

In 2025, pharmacological treatments accounted for 31.1% of the GCC swollen knee treatment market, highlighting the reliance on drug-based management for early and mid-stage care. Oral NSAIDs, topical diclofenac, and hospital-administered analgesics dominate due to their established use in primary care, emergency settings, and outpatient follow-ups. Corticosteroids remain significant but are used cautiously in diabetic patients due to potential complications in glucose management. Non-pharmacological treatments are gaining traction with expanded rehabilitation networks, while surgical treatments are shifting towards minimally invasive arthroscopy and shorter recovery pathways.

Minimally invasive procedures are projected to grow at a 5.98% CAGR through 2031, driven by physician acceptance of viscosupplementation and PRP, improved imaging-guided delivery, and patient preference for non-surgical options. These procedures align with ambulatory care economics, offering faster delivery and higher per-episode value. Anika Therapeutics reported 16% growth in international osteoarthritis pain management revenue in 2024, supported by geographic expansion into markets like the GCC. This trend is reshaping the treatment mix, moving care towards planned outpatient procedures over repeat symptomatic medication.

By Cause Or Clinical Indication: Osteoarthritis As Anchor, Sports Injury As Growth Engine

Osteoarthritis led the GCC swollen knee treatment market in 2025 with a 32.4% share, driven by obesity trends, an aging population, and improved early diagnosis of degenerative diseases. Obesity-related cytokines like leptin and TNF-α are linked to synovial inflammation, intensifying some cases through metabolic pathways. Rheumatoid arthritis and other inflammatory conditions, though smaller in volume, require complex biologic and specialist care. Secondary cases like bursitis, tendinitis, and post-traumatic swelling remain significant, especially in labor-intensive sectors, ensuring a diverse clinical mix in the market.

Sports injuries are forecasted to grow at a 6.25% CAGR from 2026 to 2031, making them the fastest-growing indication in the GCC swollen knee treatment market. This growth is fueled by investments in youth sports, organized athletic participation, and treatments for ligament injuries and training-related swelling. The UAE data highlights a male-skewed burden of knee osteoarthritis, linked to the active expatriate workforce. The demand is shifting towards active patients seeking structured recovery, reflecting a transformation in care episodes and patient expectations.

By Route Of Administration: Oral Entrenched, Injectable Gaining Institutional Ground

Oral therapies held a 28.77% share in 2025, maintaining their dominance in the GCC swollen knee treatment market. Oral NSAIDs are widely prescribed and distributed, offering convenience in early-stage pain management and conservative care. Topical products are gaining visibility for targeted pain relief, while procedural routes like arthrocentesis and radiofrequency are building credibility in specialist centers. Oral therapies remain entrenched even as the market diversifies its treatment routes.

Injectable routes are projected to grow at a 6.78% CAGR through 2031, supported by evidence for PRP and hyaluronic acid use and their role as bridge therapies between oral treatments and surgery. A 2025 review validated the efficacy of at least two PRP injections for sustained results over 24 weeks. The GCC's 2024 corticosteroid consumption of 3,300 tons, valued at USD 670 million, highlights an established ecosystem for injectable therapies. This infrastructure supports the expansion of knee-specific injectables, transitioning them from niche to standardized care.

By End User: Hospitals Anchor Demand, Specialist Clinics Reset The Growth Equation

Hospitals accounted for 35.88% of the GCC swollen knee treatment market in 2025, reflecting their role in acute care, post-surgical management, and complex knee cases. Tertiary facilities provide deeper formularies, broader device access, and stable staffing for procedures like aspiration and injections. Ambulatory surgical centers are gaining relevance with private participation and faster discharge models, while physiotherapy and rehabilitation centers capture more volume as musculoskeletal recovery becomes structured post-injection or surgery.

Orthopedic and sports medicine clinics are projected to grow at a 7.44% CAGR through 2031, making them the fastest-growing segment in the GCC swollen knee treatment market. Their growth is driven by a shift towards specialized care with faster patient turnover and favorable procedure economics. Burjeel Holdings expanded capacity with the Burjeel Orthopedic Institute in Abu Dhabi in 2025, focusing on surgery, sports medicine, and rehabilitation. Digital monitoring tools are enhancing post-procedure adherence, positioning clinics to manage the full cycle of care and reshaping patient relationship dynamics in the market.

Geography Analysis

In 2025, Saudi Arabia accounted for 26.45% of the GCC swollen knee treatment market, making it the largest national segment. This leadership is driven by its large population, a significant overweight and obese adult demographic, and a well-developed healthcare system supporting both hospital-led and outpatient orthopedic care. The country’s insurance framework enhances specialist access for expatriate workers, crucial for a treatment category requiring repeat consultations. Hikma expanded its injectable pain portfolio in Saudi Arabia in 2024, strengthening local distribution channels aligned with swollen knee management. Saudi Arabia’s combination of patient volume, reimbursement access, and supply chain efficiency solidifies its market dominance.

The UAE is projected to grow at a 7.12% CAGR through 2031, making it the fastest-growing segment in the GCC swollen knee treatment market. Growth is supported by mandatory insurance, high specialist density, and its role as a medical tourism hub for orthopedic and rehabilitation services. Burjeel’s 2025 launch of a dedicated orthopedic institute in Abu Dhabi expanded capacity in surgery, sports medicine, and rehabilitation. Additionally, Abu Dhabi’s 2024 stem cell trial for knee osteoarthritis highlights the UAE’s focus on treatment innovation and clinical advancements, driving its accelerated market growth.

Oman, Bahrain, Kuwait, and other GCC nations represent emerging opportunities in the swollen knee treatment market. Bahrain’s rising knee osteoarthritis incidence indicates latent demand that could grow with improved referral pathways. Kuwait’s high obesity rates create a significant base for pharmacological and injection-based treatments. Oman’s expanding insurance coverage is gradually improving access to specialist care beyond public hospitals. While these markets currently hold a smaller share, they are positioned for growth as orthopedic capacity, private sector involvement, and patient awareness increase.